Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Commentary|Articles|October 30, 2025
Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025
Author(s)Courtney Flaherty
Fact checked by: Ashling Wahner
Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.
Advertisement
Advertisement
Following 5 days of data-driven discussion at the
Related to this article
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Advertisement
Advertisement